Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Change in Cash (2021 - 2025)

Kezar Life Sciences' Change in Cash history spans 5 years, with the latest figure at $4.6 million for Q3 2025.

  • For Q3 2025, Change in Cash fell 30.6% year-over-year to $4.6 million; the TTM value through Sep 2025 reached $4.1 million, down 51.23%, while the annual FY2024 figure was $6.3 million, 226.05% up from the prior year.
  • Change in Cash for Q3 2025 was $4.6 million at Kezar Life Sciences, up from -$2.6 million in the prior quarter.
  • Across five years, Change in Cash topped out at $66.5 million in Q2 2022 and bottomed at -$40.9 million in Q3 2022.
  • The 5-year median for Change in Cash is -$1.6 million (2023), against an average of $931947.4.
  • The largest YoY upside for Change in Cash was 1813.62% in 2022 against a maximum downside of 1527.02% in 2022.
  • A 5-year view of Change in Cash shows it stood at $5.8 million in 2021, then tumbled by 514.6% to -$24.0 million in 2022, then surged by 137.48% to $9.0 million in 2023, then dropped by 23.39% to $6.9 million in 2024, then crashed by 33.71% to $4.6 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Change in Cash are $4.6 million (Q3 2025), -$2.6 million (Q2 2025), and -$4.7 million (Q1 2025).